Skip to main content
Premium Trial:

Request an Annual Quote

PamGene Licenses Tech to Innogenetics for Diagnostic Tests

NEW YORK, May 27 (GenomeWeb News) - PamGene has exclusively licensed its microarray technology to Innogenetics for development of multiple-parameter nucleic acid-and protein diagnostics in the area of infectious diseases, genetic testing and neurodegeneration, the companies said today.


Under the agreement, Innoenetics of Gent, Belgium will be able to develop tests in these areas for use on PamGene's PamStation 12 instruments. The license may be extended to oncology applications.  The parties did not disclose the exact financial terms of the agreement, but said it includes an upfront payment as well as milestone fees when tests are launched on the market, and royalties on sales of these tests.


Innogenetics said it selected PamGene because PamGene's technology will allow the company to develop tests that can assess 400 different parameters in a single sample run-ten times the number of parameters the company is currently able to assess per run with its existing technology.


The companies said the first set of tests is expected to "reach the market" in 2006.


PamGene, of Den Bosch, The Netherlands, markets a three-dimensional microarary technology. The PamChip standard or custom microarrays are built to the format of a 1x3-inch microscope glass slide. The slips are made of plastic laminate sandwiching a porous metal oxide that contains four array areas, on which up to 400 three-dimensional spots of oligonucleotides, proteins, peptides, or DNA-fragments are spotted by ink jet. Instead of being contained on a surface, these molecules cleave to the insides of capillaries within the metal oxide, allowing hybridization while the sample flows through the capillaries.


PamGene raised €10 Million last July in a second fundraising round.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.